With a number of calculated actions and advancements, Synbiotic, the German industrial hemp and cannabis group, is advancing toward the bioeconomy and hemp sector. Through the acquisition of significant market participants and significant government assistance, Synbiotic is establishing itself as a pioneer in sustainable production and innovation.
Government backing for the sustainable manufacture of Synbiotic
Synbiotic recently released a press release announcing that the Federal Ministry for Economic Affairs and Climate Protection (BMWK) is contributing 1.6 million euros to the industrial bio-economy sector to fund a hemp farm project. The purpose of this financing is to advance the development and implementation of automated and AI-supported industrial processes for the processing of biogenic raw materials, such as the cultures of agricultural peatlands, hemp, and miscanthus.
At Hanf Farm GmbH, Rafael Dulon serves as the managing director. He thanked them for their support and emphasized how important it was to achieving their goal of producing organic raw materials in an efficient and sustainable manner. The initiative holds significance for the industrial bioeconomy, as it offers prospects for enhanced productivity, sustainability, and further advancements in the field.
Purchasing Ilesol Pharmaceutics
With the purchase of Ilesol Pharmaceuticals, a Croatian business that specializes in cannabinoid extracts and isolates, Synbiotic’s strategic expansion proceeded. Ilesol is a valuable addition to Synbiotic’s supply chain, offering a range of natural cosmetics infused with CBD and a 3,400 m2 production facility.
Managing Director of Synbiotic, highlighted the competitive advantage of having in-house hemp and cannabis extract production and processing capabilities. With this acquisition, Synbiotic is well-positioned in the expanding market for CBD isolates and hemp extracts. The strategies include taking advantage of the rising demand across a number of industries, such as cosmetics and possibly new food uses.
Robust expansion following legalization
Germany’s historic decision to legalize cannabis to some extent was greeted by a spike in orders from Synbiotic’s subsidiary, Bushdoctor. Bushdoctor, a veteran in the cannabis sector with over 25 years of experience, is adjusting to match the growing demand, with 80% of current orders coming from Germany. In order to enhance customer service and acquisition, strategic initiatives are being implemented, such as a redesigned shop system and focused marketing campaigns. Synbiotic’s overarching marketing strategy leverages its established presence and product portfolio to take advantage of the changing market dynamics.
The management of Synbiotic is eager to make the business a major force in Europe, not just the German market. With strategic efforts in place and acquisitions like Ilesol, Synbiotic is well-positioned to take advantage of the opportunities given by the changing cannabis regulatory landscape. Synbiotic’s Chief Communication Officer, Emilio Ropero, reaffirmed the company’s dedication to long-term expansion via thorough marketing plans and wise use of available market prospects.
To sum up, Synbiotic’s latest advancements highlight the company’s dedication to sustainability, creativity, and calculated expansion within the hemp sector. Synbiotic is well-positioned to take the lead in determining the direction of industrial hemp and cannabis in Europe thanks to government backing, wise acquisitions, and an optimistic outlook.